Homepage
Healthcare · Drug Manufacturers - General · United States · Updated May 11, 1:54pm
$7.46
Price
$63.3M
Market Cap
115
Employees
1.79
Beta
Henry H. Ji
CEO
Business Description
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Business History
Price Overview
Last updated: May 11, 2026 1:54pm (just now)$7.46
-0.37 (-4.67%)
Day Range
$7.40 – $8.01
52-Week Range
$3.92 – $34.27
50-Day MA
$7.75
200-Day MA
$14.06
Volume
53,679.65
Share Structure
Outstanding
8,491,270.00
Float
7,008,830.00
Free Float
82.5%
High free float
— 82.5% of shares trade freely, ~17.5% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (7.0M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.20
Stock Price: $7.46
EPS (Diluted): -36.48
EPS (Diluted): -36.48
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.65
Stock Price: $7.46
Total Equity: -$207.78M
Shares: 11,034,000
Total Equity: -$207.78M
Shares: 11,034,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.54
Market Cap: $63.30M
Total Debt: $119.39M
Cash: $4.96M
EBITDA: -$267.68M
Total Debt: $119.39M
Cash: $4.96M
EBITDA: -$267.68M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$262.2M
Market Cap: $63.30M
Total Debt: $119.39M
Cash: $4.96M
Total Debt: $119.39M
Cash: $4.96M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
49.7%
Gross Profit: $15.03M
Revenue: $30.25M
Revenue: $30.25M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-900.1%
Operating Income: -$272.30M
Revenue: $30.25M
Revenue: $30.25M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,185.8%
Net Income: -$358.73M
Revenue: $30.25M
Revenue: $30.25M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
190.5%
Net Income: -$358.73M
Total Equity: -$207.78M
Total Equity: -$207.78M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
1,032.0%
Operating Income: -$272.30M
Tax Rate: 0.0%
Equity: -$207.78M
Total Debt: $119.39M
Cash: $4.96M
Tax Rate: 0.0%
Equity: -$207.78M
Total Debt: $119.39M
Cash: $4.96M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.08
Current Assets: $38.36M
Current Liabilities: $483.65M
Current Liabilities: $483.65M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.57
Short-Term Debt: $92.28M
Long-Term Debt: $27.12M
Total Debt: $119.39M
Total Equity: -$207.78M
Long-Term Debt: $27.12M
Total Debt: $119.39M
Total Equity: -$207.78M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$2.74
Revenue: $30.25M
Shares: 11,034,000
Shares: 11,034,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-18.83
Total Equity: -$207.78M
Shares: 11,034,000
Shares: 11,034,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$0.33
Operating CF: $3.82M
CapEx: -$133,000
Shares: 11,034,000
CapEx: -$133,000
Shares: 11,034,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $7.46
Stock Price: $7.46
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$358.73M
Net Income: -$358.73M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SCLX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $31.3M | $38.0M | $46.7M | $56.6M | $30.3M |
| Cost of Revenue | $3.6M | $10.8M | $15.7M | $16.7M | $15.2M |
| Gross Profit | $27.7M | $27.2M | $31.1M | $39.9M | $15.0M |
| Operating Expenses | $63.5M | $77.9M | $136.5M | $123.3M | $287.3M |
| Operating Income | -$35.8M | -$50.6M | -$105.4M | -$83.4M | -$272.3M |
| Net Income | -$88.4M | -$23.4M | -$114.3M | -$72.8M | -$358.7M |
| EBITDA | -$72.9M | -$9.3M | -$109.1M | -$66.8M | -$267.7M |
| EPS | $-23.29 | $-6.09 | $-44.85 | $-19.43 | $-36.48 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.3M | $2.2M | $3.9M | $3.3M | $5.0M |
| Total Current Assets | $23.0M | $29.6M | $46.8M | $41.5M | $38.4M |
| Total Assets | $77.9M | $86.5M | $101.3M | $93.0M | $365.0M |
| Current Liabilities | $169.4M | $44.8M | $250.4M | $259.6M | $483.7M |
| Long-Term Debt | $95.5M | $0 | $17.0M | $845,000 | $27.1M |
| Total Liabilities | $301.8M | $50.3M | $274.2M | $285.6M | $576.7M |
| Total Equity | -$223.9M | $36.2M | -$172.9M | -$192.6M | -$207.8M |
| Retained Earnings | -$352.6M | -$375.9M | -$490.2M | -$563.1M | -$921.8M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$28.7M | -$21.3M | -$20.7M | $19.3M | $3.8M |
| Capital Expenditure | $0 | -$2.1M | $-330,000 | $0 | $-133,000 |
| Free Cash Flow | -$28.7M | -$23.3M | -$21.0M | $19.3M | $3.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$10.0M | $0 | $0 |
| Net Change in Cash | $-501,000 | -$2.2M | $2.5M | -$1.5M | $1.7M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$189.0M $189.0M – $189.0M
|
$608.5M $608.5M – $608.5M
|
$944.2M $944.2M – $944.2M
|
$1.1B $1.1B – $1.1B
|
| EBITDA |
-$160.4M -$160.4M – -$160.4M
|
-$516.5M -$516.5M – -$516.5M
|
-$801.5M -$801.5M – -$801.5M
|
-$926.2M -$926.2M – -$926.2M
|
| Net Income |
$8.1M $8.1M – $8.1M
|
$74.8M $74.8M – $74.8M
|
$120.3M $120.3M – $120.3M
|
$138.8M $138.8M – $138.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +21.4% | +22.9% | +21.1% | -46.5% |
| Gross Profit Growth | -1.6% | +14.0% | +28.5% | -62.3% |
| Operating Income Growth | -41.3% | -108.2% | +20.9% | -226.5% |
| Net Income Growth | +73.6% | -389.3% | +36.3% | -392.7% |
| EBITDA Growth | +87.2% | -1,072.8% | +38.8% | -300.7% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-17 | Ma Stephen Hoi | P-Purchase | 650,000.00 | $1.20 | $780,000 |
| 2026-04-16 | Ji Henry | P-Purchase | 3,250,000.00 | $1.20 | $3.9M |
| 2026-04-17 | Ji Henry | S-Sale | 650,000.00 | $1.20 | $780,000 |
| 2025-12-26 | Scilex Holding Co | S-Sale | 3,689,016.00 | $0.75 | $2.8M |
| 2025-12-29 | Scilex Holding Co | S-Sale | 7,310,984.00 | $0.66 | $4.8M |
| 2025-12-30 | Scilex Holding Co | S-Sale | 9,657,300.00 | $0.54 | $5.2M |
| 2025-10-08 | Wu Yue Alexander | A-Award | 20,000.00 | $17.58 | $351,600 |
| 2025-10-08 | Ma Stephen Hoi | A-Award | 60,000.00 | $17.58 | $1.1M |
| 2025-10-08 | Chun Jay | A-Award | 20,000.00 | $17.58 | $351,600 |
| 2025-10-08 | Ji Henry | A-Award | 120,000.00 | $17.58 | $2.1M |
| 2025-10-08 | Followwill Dorman | A-Award | 20,000.00 | $17.58 | $351,600 |
| 2025-01-21 | SCLX Stock Acquisition JV LLC | J-Other | 3,250,000.00 | $0.00 | $325 |
| 2025-01-16 | SCLX Stock Acquisition JV LLC | J-Other | 779,371.00 | $0.00 | $78 |
| 2025-01-02 | SCLX Stock Acquisition JV LLC | J-Other | 5,000,000.00 | $0.00 | $500 |
| 2024-12-18 | SHAH JAISIM | P-Purchase | 30,000.00 | $0.46 | $13,800 |
| 2024-12-16 | Chun Jay | A-Award | 100,000.00 | $0.50 | $50,450 |
| 2024-12-16 | Followwill Dorman | A-Award | 100,000.00 | $0.50 | $50,450 |
| 2024-12-16 | Wu Yue Alexander | A-Award | 100,000.00 | $0.50 | $50,450 |
| 2024-10-31 | Ji Henry | P-Purchase | 8,888.00 | $0.94 | $8,351 |
| 2024-10-29 | SHAH JAISIM | P-Purchase | 32,000.00 | $0.99 | $31,670 |
No community reviews yet for SCLX.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27